Data Availability Statement The study data are available via the Pharmaceutical Benefits Scheme, or by contacting the corresponding author. Supporting Information Filename Description ceo70091-sup-0001-FigureS1.docxWord 2007 document , 667 KB Figure S1: The rate of monthly intravitreal injection prescriptions in Australia per indication between 2019 and 2024 for (a) aflibercept, (b) ranibizumab, (c) dexamethasone, (d) faricimab-svoa and (e) brolucizumab.